A simple validated LC-UV method for the phytochemical analysis of four bioactive quassinoids, 13α(21)-epoxyeurycomanone (EP), eurycomanone (EN), 13α,21-dihydroeurycomanone (ED) and eurycomanol (EL) in rat plasma following oral (200 mg/kg) and intravenous administration (10 mg/kg) of a standardized extract Fr 2 of Eurycoma longifolia Jack was developed for pharmacokinetic and bioavailability studies. The extract Fr 2 contained 4.0%, 18.5%, 0.7% and 9.5% of EP, EN, ED and EL, respectively. Following intravenous administration, EP displayed a relatively longer biological half-life (t ½ = 0.75 ± 0.25 h) due primarily to its lower elimination rate constant (k e ) of 0.84 ± 0.26 h -1 ) when compared with the t ½ of 0.35 ± 0.04 h and k e of 2.14 ± 0.27 h -1 , respectively of EN. Following oral administration, EP showed a higher C max of 1.61± 0.41 μg/mL over that of EN (C max = 0.53 ± 0.10 μg/mL). The absolute bioavailability of EP was 9.5-fold higher than that of EN, not because of chemical degradation since both quassinoids were stable at the simulated gastric pH of 1. Instead, the higher log K ow value of EP (-0.43) contributed to greater membrane permeability over that of EN (log K ow = -1.46) at pH 1. In contrast, EL, being in higher concentration in the extract than EP, was not detected in the plasma after oral administration because of substantial degradation by the gastric juices after 2 h. Similarly, ED, being unstable at the acidic pH and together with its low concentration in Fr 2, was not detectable in the rat plasma. In conclusion, upon oral administration of the bioactive standardized extract Fr 2, EP and EN may be the only quassinoids contributing to the overall antimalarial activity; this is worthy of further investigation.
Eurycoma longifolia Jack, a tall tree belonging to the Simaroubaceae family, is found mainly in the tropical forest of southeast Asia and is popularly known as 'Tongkat Ali' in Malaysia, 'Pasak Bumi' in Indonesia and 'Cay ba binh' in Vietnam [1] . The roots of the plant have been used as folk medicine for healing boils, wound ulcers, syphilis, intermittent fever and bleeding gums [2, 3] . The plant has been researched for anabolic [4] , cytotoxic [5, 6] , male fertility [7] , sexual improvement [8] and anti-malarial activities [1, 6, [9] [10] [11] . Recently, increasing development of a new artemisinin-resistance of Plasmodium falciparum in the Mekong region of the Thai-Cambodian border has triggered a global problem [12] . Artemisinin-based combination therapies (ACTs) have been recommended by WHO as the frontline treatment for severe and uncomplicated P. falciparum malaria, and, presently, there are no new drugs to replace ACTs. Thus, novel therapeutic agents and newer ACTs have to be available in the near future. A previous study reported that eurycomanone (EN), 13α(21)-epoxyeurycomanone (EP), 13α,21dihydroeurycomanone (ED) and eurycomanol (EL), four quassinoids isolated from the root of E. longifolia ( Figure 1 ), exhibited potent antiplasmodial activity against chloroquine-resistant P. falciparum [10] . Subsequently, a standardized E. longifolia root extract (Fr 2), enriched with these quassinoids, was reported to show good synergistic anti-plasmodial activity of 3.4-fold less potency than artemisinin against the in vitro culture of matured NPC Natural Product Communications 2011 Vol. 6 No. 3 337 -341 4-aminoquinoline-resistant P. falciparum schizonts from patient isolates at the Thai-Myanmar border [11] . In contrast, these quassinoids, when tested singly against the chloroquine-resistant isolates from the malaria patients of the Gombak district hospital in Malaysia, were 17.5-to 291.5-fold less potent [10] .
Despite promising antimalarial properties, very little is known about the oral bioavailability of the quassinoids. Pharmacokinetic studies can provide predictions of bioavailability, the effective dose, the dosage regimen, the toxicity, and stability of a bioactive substance. A previous study reported that EN has low bioavailability and poor membrane permeability due to the compound being highly polar and/or experiencing first-pass metabolism [13] . The present study investigated the pharmacokinetic and bioavailability parameters of the other major bioactive quassinoids, EP, EL and ED in the extract Fr 2 and compared them with EN following oral and intravenous administration in rats. The physico-chemical properties of pH stability and partition coefficient of the quassinoids influencing their absorption in the gastro-intestinal tract were also investigated, and subsequently, their relationship to the overall oral antimalarial activity of Fr 2 was discussed.
The calibration curves over the concentrations ranging from 0.1 to 25.0 μg/mL were linear for EP, EN, ED and EL with a mean slope (± standard error of mean) of 2617.2 ± 17.9, 5094.8 ± 87.1, 3074.2 ± 34.9 and 1266.7 ± 35.9, respectively, and a mean intercept of -192.5 ± 56.9, -44.4 ± 49.6, -158.6 ± 113.9 and -573. Figure 3B ; 13α,21dihydroeurycomanone (ED) in Figure 3C and eurycomanol (EL) in Figure 3D , at 37°C at pH 1, 4 and 7. Each experiment was conducted in duplicate. * Significant level at p < 0.05.
3:1, whereas their limits of quantification were 0.5, 0.1, 0.5 and 1.0 μg/mL, respectively at a signal-to-noise ratio of 10:1.Their relative standard deviations (RSD) for precision of between-day and within-day analysis were less than 13.0%. In addition, the percentage errors of accuracy for between-day and within-day assays were from -13.0 to 7.0% for the four quassinoids. The recovery values from the sample preparation ranged from 97.7 to 102.0%, 95.3 to 104.8%, 92.0 to 103.2% and 93.5 to 103.4% for EP, EN, ED and EL, respectively.
The rat plasma levels of EP, EN and EL showed a rapid decline after intravenous administration of 10 mg/kg Fr 2 (Figure 2A ), but ED was not detected on analysis of the plasma. Upon oral administration of Fr 2 at 200 mg/kg, EP and EN showed a gradual increase in plasma concentration approaching T max , followed by a gradual decline after 24 h ( Figure 2B ). The C max value of EP was significantly much higher (P < 0.05) than that of EN (Table 1) , even though EP was 4.6-fold lower in concentration than EN in Fr 2. Consequently, the AUC 0→∞ of EP was also bigger than that of EN ( Figure 2B ), thus, yielding their absolute bioavailability as 24.7 and 2.6%, respectively. The 9.5-fold increase in absolute bioavailability of EP over EN was due to the 13α(21)-epoxy analogue possessing a higher lipid solubility (hydrophobicity). Chemical degradation was not involved since both quassinoids were stable over the different pH conditions studied ( Figure  3A-B) . Previous study also supported that EN has low bioavailability due to poor lipid solubility [13] . On the other hand, both ED and EL were not detected in the plasma. Chemical stability studies provided evidence of ED showing chemical degradation during 6 hours of incubation at 37˚C in a medium simulating the gastric juices at pH 1( Figure 3C ). Furthermore, the concentration of ED was also very low in Fr 2. Similarly, EL experienced substantial degradation at pH 1 after 2 hours of incubation ( Figure 3D ), and also exhibited the lowest lipid solubility (hydrophobicity) amongst the quassinoids studied, as depicted by the lowest log K ow value ( Table 2) . These observations provided a plausible explanation of poor membrane permeability in the gastrointestinal tract [14] and absence of EL in the oral rat plasma.
In conclusion, the present study demonstrated that only EP and EN in the standardized E. longifolia extract Fr 2 were orally absorbed. ED and EL decomposed at the acidic pH of the gastric juices and could not contribute to any in vivo synergistic antimalarial activity of the extract administered orally. Despite displaying a lower bioavailability, EN showed a 1.9-fold higher antimalarial activity [10] at 4.6-fold higher concentration than EP in Fr 2. Hence, both EP and EN should be further studied as potential oral antimalarial agents and their optimization in the extract is worthy of further investigation. , hydrochloric acid and noctanol used in the preparation were purchased from Merck (Darmstadt, Germany).
Experimental

Plant material and chemicals: Powdered
Plant extraction:
The air-dried powdered roots of E. longifolia (11.6 kg) were extracted with 6 x 4 L of 95% MeOH for 6 days at 60ºC. The combined methanol extract was evaporated to dryness to yield 485 g of dark brown residue, which was next chromatographed on a Diaion HP 20 column with H 2 O-MeOH (1:0-0:1) gradient to afford 4 fractions (Fr 1-4). Fraction 2 (Fr 2) was collected and concentrated under vacuum to give the desired extract (52.2 g). The quassinoids, 13α(21)-epoxyeurycomanone (EP, purity > 95%), eurycomanone (EN, purity > 96%), 13α,21-dihydroeurycomanone (ED, purity > 95%) and eurycomanol (EL, purity > 96%) were isolated and purified from Fr 2 following the protocol described previously [15] . The isolated quassinoids were used as external standards for the standardization of Fr 2, method validation, and quantification in plasma samples. The purity of the compounds was determined with Empower 2 workstation software (Waters, Milford, MA, USA) operated in a Waters Delta Prep HPLC system equipped with a Waters 2996 photodiode array detector.
Bioavailability study: The bioavailability study was carried out as described previously [13] . Briefly, the standardized extract Fr 2 of E. longifolia containing 4.0%, 18.5%, 0.7% and 9.5% of EP, EN, ED and EL, respectively was orally and intravenously administered to the 6 male Sprague-Dawley rats on separate occasions. Twelve hours prior to the study, food pellets were removed and only water was given ad libitum.
The animals were only given food after collection of blood sample at 6 h. Fr 2 was dissolved in normal saline to give a concentration of 35.0 mg/mL. The preparation of 10.0 mg/kg was then administered intravenously into the rat tail vein. After a 2-week washout period, all the animals were orally given 200 mg/kg of Fr 2 (60.0 mg/mL in normal saline) with an oral feeding needle (Popper and Sons Inc., UK). Blood samples of 0.5 mL were removed from the tail vein of the rats at 0 (pre-dose), 0.33, 0.67, 1, 1.33, 1.67, 2, 2.5, 3, 4 and 6 h after intravenous injection and at 0 (pre-dose), 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10 and 24 h after oral administration. The blood samples were collected into microcentrifuge tubes containing approximately 5 mg sodium heparin and then centrifuged at 3000 g for 15 min. The plasma was collected and kept frozen at -20°C prior to HPLC analysis.
HPLC assay: Plasma levels of EP, EN, ED and EL were measured using a validated HPLC method developed with UV detection. All frozen plasma samples were thawed at room temperature. A 50 μL aliquot of plasma was then transferred into a 1.5 mL microcentrifuge tube and deproteinized by adding 2.5 μL of 70% perchloric acid. The mixture was vortex-mixed for 30 sec followed by centrifugation at 3000 g for 10 min. The clear supernatant layer was then collected into a new microcentrifuge tube prior to HPLC analysis. The liquid chromatographic system comprising a Jasco PU-980 pump (Tokyo, Japan) was connected to a Rheodyne 7725i (Cotati, CA, USA) sample injector of 20 μL injection volume, a Jasco UV-2075 Plus UV detector (Tokyo, Japan) and a Hitachi D-2500 Chromato-integrator (Tokyo, Japan). An Inertsil ODS-3 (4.6 mm i.d. × 250 mm, GL Sciences Inc., Tokyo, Japan) column, pre-connected with a guard column (Inertsil ODS-3, 4.6 mm i.d. × 50 mm, GL Sciences Inc., Tokyo, Japan) was used for the chromatographic separation. The mobile phase consisting of acetonitrile/distilled water (1:9, v/v), was delivered at a flow-rate of 1.0 mL/min at ambient room temperature. Ultraviolet detection was performed at a wavelength of 210 nm for EL and 238 nm for EP, EN and ED. The analytical method was validated and the samples were quantified following an external standard method.
Pharmacokinetics data analysis:
The following pharmacokinetic parameters were estimated from the data obtained from intravenous (i.v.) administration: elimination rate constant (k e ); biological half-life (t ½ ); volume of distribution (V d ); area under plasma concentration-time curve (AUC 0→∞ ); and clearance (CL).
The k e was calculated from the slope of the plasma concentration versus time curve (after logarithmic transformation), whereas t ½ was calculated using the relationship t ½ = ln 2/k e . As for V d , it was calculated from the relationship V d = Dose/k e ·AUC 0→∞ . The value of AUC 0→∞ was determined by adding the area from time zero to the last sampling time (AUC 0→t ) with the area from the last sampling time to infinity (AUC t→∞ ). The former was calculated using the trapezoidal method, whereas the latter was estimated by dividing the last measurable plasma drug concentration with k e . From AUC 0→∞ , CL was calculated from the relationship CL = Dose/AUC 0→∞ . Peak concentration (C max ) and time to reach C max (T max ) after oral administration were obtained from the actual data. Additionally, the absolute bioavailability values of EP, EN, ED and EL were estimated from the ratio of the AUC 0→∞ from the oral data over that of the i.v. data, normalized on dose difference [16] .
Octanol/water partition coefficient and chemical stability studies:
The lipophilicity or hydrophilicity of EP, EN, ED and EL was determined using the n-octanol/water partition coefficient (log K ow ), as previously described [13] . Briefly, the aqueous phases were prepared consisting of 0.1 M HCl at pH 1.0; 0.05 M NaH 2 PO 4 .2H 2 O adjusted with glacial acetic acid to pH 4.0, and 0.05 M Na 2 HPO 4 .2H 2 O adjusted with glacial acetic acid to pH 7.0. About 25.0 mL of each phase and 1.0 mg of Fr 2 were added to a separating funnel to yield a solution of 40.0 μg/mL. About 10.0 mL of noctanol was then added to the solution. The mixture was shaken vigorously and then allowed to stand for 2 h prior to withdrawal of samples for HPLC analysis. The concentrations of EP, EN, ED and EL were measured and the partition coefficient (log K ow ) values were then calculated from the ratios of their concentrations in the noctanol phase over that of the aqueous phase.
The chemical stability of EP, EN, ED and EL was determined at pH 1.0, 4.0 and 7.0, as described previously [13] . Briefly, the medium was maintained at 37°C for approximately 1 h before 2.0 mg of Fr 2 was added to yield a concentration of 40.0 μg/mL. Two samples of 1.0 mL each were withdrawn at intervals of 0, 0.5, 1.0, 2.0, 4.0 and 6.0 h. The concentration of EP, EN, ED and EL in each withdrawn sample was analyzed in duplicate using the HPLC method.
Statistical analysis:
Results were expressed as the mean ± S.E.M for the pharmacokinetics parameters and mean ± SD for the pH stability study. The mean of pH stability data was analyzed using Student's t-test. Values of P < 0.05 were considered as statistically significant.
